Zoetis Receives EMA Endorsement for Canine Osteoarthritis Treatment

Zoetis (ZTS) receives support from the European Medicines Agency for a new canine osteoarthritis treatment, Lenivia. The treatment targets nerve growth factor and provides relief for three months with a single injection. Zoetis generates significant revenue from companion animal products and has a robust financial health with strong margins and consistent revenue growth. The company's valuation metrics suggest it is trading near historical lows, and analyst sentiment remains positive.

The European Medicines Agency's Committee for Veterinary Medicinal Products has issued a positive opinion for the marketing authorization of Zoetis' (NYSE:ZTS) Lenivia (izenivetmab) to ease osteoarthritis pain in dogs. A decision is expected by the end of the year with a potential launch in 2026 Zoetis gains EMA panel endorsement for Lenivia for osteoarthritis pain in dogs^[1].

Lenivia is designed as an antibody therapy that reduces osteoarthritis pain in dogs for three months with a single injection by targeting nerve growth factor (NGF), a mediator of pain and inflammation. The company reported that dogs in a nine-month field study showed increased mobility and decreased pain after treatment Zoetis’ dog osteoarthritis pain treatment receives positive EU opinion^[2].

Zoetis, which generated revenue of $9.3 billion in 2024, focuses on animal health products including medicines, vaccines, diagnostics and technologies. The company's strong financial health is reflected in its gross margins of 71.5% and consistent revenue growth Zoetis’ dog osteoarthritis pain treatment receives positive EU opinion^[2].

If approved, Lenivia would join Librela (bedinvetmab) in Zoetis’ portfolio of osteoarthritis pain products for dogs. While both are monoclonal antibodies targeting NGF, Lenivia binds to a different site on NGF and is designed to provide longer-lasting pain reduction Zoetis’ dog osteoarthritis pain treatment receives positive EU opinion^[2].

The company's valuation metrics suggest it is trading near historical lows, with a P/E ratio of 24.29, P/S ratio of 6.78, and P/B ratio of 12.59 Zoetis (ZTS): EMA Supports New Canine Osteoarthritis Treatment^[3]. Analyst sentiment remains positive, with a recommendation score of 2.1 and a target price of $190.78 Zoetis (ZTS): EMA Supports New Canine Osteoarthritis Treatment^[3].